IMRX · Immuneering Corporation Class A Common Stock
View on chartInsiders & Stakes
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 2,895,273 Shares held | 4/1/2024 | View profile |
| Benjamin J. Zeskind PRESIDENT AND CEO | ▲ Buy | Open Market | 2,315,252 Shares held | 6/23/2026 | View profile |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | ▲ Buy | Open Market | 382,531 Shares held | 6/15/2026 | View profile |
| Peter Feinberg | ▲ Buy | Open Market | 135,441 Shares held | 1/12/2026 | View profile |
| Thomas J. Schall | ▲ Buy | Open Market | 74,530 Shares held | 1/15/2026 | View profile |
| Ann E. Berman Director | ▲ Buy | Open Market | 67,465 Shares held | 3/18/2024 | View profile |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | ▲ Buy | Grant | 29,598 Shares held | 3/13/2026 | View profile |
| Mallory Morales Chief Accounting Officer | ▲ Buy | Open Market | 27,533 Shares held | 10/1/2025 | View profile |
| KEATING LAURIE Director | ▲ Buy | Open Market | 14,000 Shares held | 5/16/2022 | View profile |
| Harold Eugene Brakewood Chief Business Officer | ▲ Buy | Open Market | 11,050 Shares held | 1/16/2026 | View profile |
| Amin Biren CFO, TREASURER | ▲ Buy | Open Market | 7,898 Shares held | 5/12/2022 | View profile |
| Barrett Scott CHIEF MEDICAL OFFICER | ▲ Buy | Open Market | 7,563 Shares held | 3/22/2022 | View profile |
| Michael Bookman GENERAL COUNSEL AND SECRETARY | ▲ Buy | Open Market | 4,870 Shares held | 10/1/2025 | View profile |
| Diana Hausman Director | ▲ Buy | Open Market | 3,000 Shares held | 7/2/2025 | View profile |
Transaction History
| Benjamin J. Zeskind | ▲ Buy | Open Market | 2,400 | $11K | 6/23/2026 |
| Brett Matthew Hall | ▲ Buy | Open Market | 6,035 | $25K | 6/15/2026 |
| Leah R. Neufeld | ▲ Buy | Grant | 3,628 | $16K | 3/13/2026 |
| Harold Eugene Brakewood | ▲ Buy | Open Market | 5,250 | $25K | 1/16/2026 |
| Thomas J. Schall | ▲ Buy | Open Market | 21,645 | $101K | 1/15/2026 |
| Brett Matthew Hall | ▲ Buy | Open Market | 2,298 | $11K | 1/15/2026 |
| Leah R. Neufeld | ▲ Buy | Open Market | 2,626 | $11K | 1/13/2026 |
| Peter Feinberg | ▲ Buy | Open Market | 20,000 | $87K | 1/12/2026 |
| Peter Feinberg | ▲ Buy | Open Market | 7,500 | $50K | 10/3/2025 |
| Mallory Morales | ▲ Buy | Open Market | 300 | $2K | 10/1/2025 |
| Leah R. Neufeld | ▲ Buy | Open Market | 800 | $5K | 10/1/2025 |
| Michael Bookman | ▲ Buy | Open Market | 1,020 | $7K | 10/1/2025 |
| Peter Feinberg | ▲ Buy | Open Market | 7,500 | $53K | 9/30/2025 |
| Peter Feinberg | ▲ Buy | Open Market | 5,000 | $36K | 9/29/2025 |
| Leah R. Neufeld | ▲ Buy | Grant | 11,815 | $17K | 9/15/2025 |
| Mallory Morales | ▲ Buy | Grant | 14,497 | $21K | 9/15/2025 |
| Brett Matthew Hall | ▲ Buy | Grant | 14,880 | $21K | 9/15/2025 |
| Diana Hausman | ▲ Buy | Open Market | 2,500 | $9K | 7/2/2025 |
| Diana Hausman | ▲ Buy | Open Market | 3,000 | $11K | 7/2/2025 |
| Leah R. Neufeld | ▲ Buy | Open Market | 700 | $2K | 7/2/2025 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 7,015 | $25K | 7/2/2025 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 2,985 | $10K | 7/1/2025 |
| Thomas J. Schall | ▲ Buy | Open Market | 9,500 | $35K | 6/27/2025 |
| Brett Matthew Hall | ▲ Buy | Open Market | 6,007 | $15K | 6/23/2025 |
| Brett Matthew Hall | ▲ Buy | Open Market | 7,415 | $20K | 6/20/2025 |
| Harold Eugene Brakewood | ▲ Buy | Open Market | 1,900 | $5K | 6/20/2025 |
| Peter Feinberg | ▲ Buy | Open Market | 25,000 | $63K | 6/18/2025 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 21,000 | $50K | 6/18/2025 |
| Thomas J. Schall | ▲ Buy | Open Market | 40,485 | $89K | 6/17/2025 |
| Mallory Morales | ▲ Buy | Grant | 4,458 | $7K | 9/15/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 100 | $307 | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 300 | $920 | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 100 | $305 | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 600 | $2K | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 10 | $30 | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 280 | $832 | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 398,600 | $1.2M | 4/1/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 10 | $30 | 4/1/2024 |
| Thomas J. Schall | ▲ Buy | Open Market | 2,900 | $7K | 3/22/2024 |
| Peter Feinberg | ▲ Buy | Open Market | 25,000 | $64K | 3/22/2024 |
| Harold Eugene Brakewood | ▲ Buy | Open Market | 3,900 | $10K | 3/22/2024 |
| Mallory Morales | ▲ Buy | Open Market | 393 | $1K | 3/22/2024 |
| Mallory Morales | ▲ Buy | Open Market | 1,107 | $3K | 3/21/2024 |
| Brett Matthew Hall | ▲ Buy | Open Market | 7,000 | $20K | 3/20/2024 |
| Leah R. Neufeld | ▲ Buy | Open Market | 3,818 | $11K | 3/20/2024 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 20,000 | $55K | 3/19/2024 |
| Peter Feinberg | ▲ Buy | Open Market | 25,000 | $64K | 3/19/2024 |
| Ann E. Berman | ▲ Buy | Open Market | 57,965 | $123K | 3/18/2024 |
| Peter Feinberg | ▲ Buy | Open Market | 45,024 | $104K | 3/18/2024 |
| Peter Feinberg | ▲ Buy | Open Market | 4,976 | $15K | 3/18/2024 |
| Leah R. Neufeld | ▲ Buy | Grant | 6,211 | $10K | 3/15/2024 |
| Brett Matthew Hall | ▲ Buy | Grant | 6,211 | $10K | 3/15/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 400,000 | $856K | 3/15/2024 |
| Michael Bookman | ▲ Buy | Grant | 1,448 | $2K | 3/15/2024 |
| Mallory Morales | ▲ Buy | Grant | 4,344 | $7K | 3/15/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 345,266 | $1.1M | 3/14/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 98,570 | $418K | 3/14/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 54,215 | $291K | 3/14/2024 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 11,040 | $66K | 3/14/2024 |
| Benjamin J. Zeskind | ▲ Buy | Option Exercise | 2,500 | $8K | 12/22/2022 |
| Brett Matthew Hall | ▲ Buy | Open Market | 2,551 | $10K | 5/25/2022 |
| Michael Bookman | ▲ Buy | Open Market | 1,000 | $5K | 5/17/2022 |
| KEATING LAURIE | ▲ Buy | Open Market | 7,000 | $35K | 5/16/2022 |
| Amin Biren | ▲ Buy | Open Market | 1,000 | $4K | 5/12/2022 |
| Benjamin J. Zeskind | ▲ Buy | Option Exercise | 2,000 | $6K | 4/12/2022 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 3,000 | $24K | 3/23/2022 |
| Brett Matthew Hall | ▲ Buy | Open Market | 1,050 | $8K | 3/23/2022 |
| Barrett Scott | ▲ Buy | Open Market | 900 | $7K | 3/22/2022 |
| Peter Feinberg | ▲ Buy | Open Market | 6,667 | $45K | 3/15/2022 |
| Ann E. Berman | ▲ Buy | Open Market | 6,000 | $38K | 3/15/2022 |
| Benjamin J. Zeskind | ▲ Buy | Option Exercise | 2,000 | $6K | 2/28/2022 |
| Brett Matthew Hall | ▲ Buy | Grant | 322,691 | — | 12/22/2021 |
| Peter Feinberg | ▲ Buy | Open Market | 4,750 | $116K | 9/20/2021 |
| Peter Feinberg | ▲ Buy | Open Market | 5,750 | $124K | 9/13/2021 |
| Benjamin J. Zeskind | ▲ Buy | Open Market | 2,083 | $48K | 9/13/2021 |
| Peter Feinberg | ▲ Buy | Open Market | 349 | $7K | 9/13/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026
Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.